S&P 500   3,996.01 (-1.86%)
DOW   33,936.45 (-1.43%)
QQQ   286.50 (-2.07%)
AAPL   145.87 (-1.31%)
MSFT   249.07 (-2.33%)
META   121.92 (-1.27%)
GOOGL   99.23 (-1.20%)
AMZN   90.93 (-3.40%)
TSLA   181.09 (-7.07%)
NVDA   165.33 (-2.03%)
NIO   12.79 (-2.59%)
BABA   90.01 (-0.06%)
AMD   73.17 (-2.41%)
T   18.72 (-1.58%)
MU   53.96 (-1.32%)
CGC   4.28 (-0.23%)
F   13.43 (-3.10%)
GE   84.78 (-2.42%)
DIS   95.77 (-3.68%)
AMC   7.50 (-8.20%)
PYPL   73.20 (-1.96%)
PFE   50.60 (-0.61%)
NFLX   311.40 (-2.81%)
S&P 500   3,996.01 (-1.86%)
DOW   33,936.45 (-1.43%)
QQQ   286.50 (-2.07%)
AAPL   145.87 (-1.31%)
MSFT   249.07 (-2.33%)
META   121.92 (-1.27%)
GOOGL   99.23 (-1.20%)
AMZN   90.93 (-3.40%)
TSLA   181.09 (-7.07%)
NVDA   165.33 (-2.03%)
NIO   12.79 (-2.59%)
BABA   90.01 (-0.06%)
AMD   73.17 (-2.41%)
T   18.72 (-1.58%)
MU   53.96 (-1.32%)
CGC   4.28 (-0.23%)
F   13.43 (-3.10%)
GE   84.78 (-2.42%)
DIS   95.77 (-3.68%)
AMC   7.50 (-8.20%)
PYPL   73.20 (-1.96%)
PFE   50.60 (-0.61%)
NFLX   311.40 (-2.81%)
S&P 500   3,996.01 (-1.86%)
DOW   33,936.45 (-1.43%)
QQQ   286.50 (-2.07%)
AAPL   145.87 (-1.31%)
MSFT   249.07 (-2.33%)
META   121.92 (-1.27%)
GOOGL   99.23 (-1.20%)
AMZN   90.93 (-3.40%)
TSLA   181.09 (-7.07%)
NVDA   165.33 (-2.03%)
NIO   12.79 (-2.59%)
BABA   90.01 (-0.06%)
AMD   73.17 (-2.41%)
T   18.72 (-1.58%)
MU   53.96 (-1.32%)
CGC   4.28 (-0.23%)
F   13.43 (-3.10%)
GE   84.78 (-2.42%)
DIS   95.77 (-3.68%)
AMC   7.50 (-8.20%)
PYPL   73.20 (-1.96%)
PFE   50.60 (-0.61%)
NFLX   311.40 (-2.81%)
S&P 500   3,996.01 (-1.86%)
DOW   33,936.45 (-1.43%)
QQQ   286.50 (-2.07%)
AAPL   145.87 (-1.31%)
MSFT   249.07 (-2.33%)
META   121.92 (-1.27%)
GOOGL   99.23 (-1.20%)
AMZN   90.93 (-3.40%)
TSLA   181.09 (-7.07%)
NVDA   165.33 (-2.03%)
NIO   12.79 (-2.59%)
BABA   90.01 (-0.06%)
AMD   73.17 (-2.41%)
T   18.72 (-1.58%)
MU   53.96 (-1.32%)
CGC   4.28 (-0.23%)
F   13.43 (-3.10%)
GE   84.78 (-2.42%)
DIS   95.77 (-3.68%)
AMC   7.50 (-8.20%)
PYPL   73.20 (-1.96%)
PFE   50.60 (-0.61%)
NFLX   311.40 (-2.81%)
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$151.39
-5.86 (-3.73%)
(As of 12/5/2022 03:29 PM ET)
Add
Compare
Today's Range
$151.39
▼
$156.88
50-Day Range
$126.59
▼
$157.25
52-Week Range
$119.64
▼
$169.98
Volume
14,519 shs
Average Volume
553,761 shs
Market Capitalization
$9.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$202.50

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
31.9% Upside
$202.50 Price Target
Short Interest
Healthy
3.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
1.37mentions of Jazz Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$8.52 M Sold Last Quarter
Proj. Earnings Growth
9.88%
From $14.77 to $16.23 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.82 out of 5 stars

Medical Sector

40th out of 1,033 stocks

Pharmaceutical Preparations Industry

16th out of 502 stocks

See Top Rated MarketRank™ Stocks Here
JAZZ stock logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

November 30, 2022 | marketbeat.com
Struggling Axsome Stock Could Bounce Back on Drug Trial Success (JAZZ)
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.
November 23, 2022 | marketbeat.com
Three CBD Stocks to Dominate a Budding Industry  (JAZZ)
The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.
December 5, 2022 | benzinga.com
Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy
November 28, 2022 | finance.yahoo.com
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting
November 21, 2022 | finance.yahoo.com
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option
November 18, 2022 | finance.yahoo.com
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)
November 14, 2022 | finance.yahoo.com
STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING
November 11, 2022 | finance.yahoo.com
Implied Volatility Surging for Jazz Pharmaceuticals (JAZZ) Stock Options
November 11, 2022 | finance.yahoo.com
Jazz Pharmaceuticals Third Quarter 2022 Earnings: EPS Misses Expectations
November 10, 2022 | msn.com
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance
November 10, 2022 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals
November 9, 2022 | finanznachrichten.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
November 9, 2022 | finance.yahoo.com
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
November 8, 2022 | finance.yahoo.com
Why Jazz Pharmaceuticals (JAZZ) Might Surprise This Earnings Season
November 3, 2022 | finanznachrichten.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
November 3, 2022 | finance.yahoo.com
Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
October 31, 2022 | finance.yahoo.com
Zacks.com featured highlights include Albemarle, Chevron, Jazz Pharmaceuticals and Cummins
October 26, 2022 | finance.yahoo.com
Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval
October 26, 2022 | marketwatch.com
Oligonucleotide Therapeutics Market Size with SWOT Analysis is Likely to Accelerate Industry Growth in Healthcare, Pharmaceuticals
October 24, 2022 | finance.yahoo.com
Wall Street Analysts Predict a 48% Upside in Jazz (JAZZ): Here's What You Should Know
October 20, 2022 | marketwatch.com
Jazz Pharmaceuticals, Zymeworks in Zanidatamab License Pact
October 19, 2022 | msn.com
Zymeworks and Jazz Pharmaceuticals ink $50M deal with potential for more
October 19, 2022 | finance.yahoo.com
Morrisville drugmaker sees promise in depression treatment, advances to pivotal study
October 19, 2022 | benzinga.com
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
October 19, 2022 | seekingalpha.com
Zymeworks surges 14% on license deal with Jazz for cancer drug zanidatamab
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings
11/09/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
CIK
1232524
Web
www.jazzpharma.com
Phone
(531) 634-7800
Fax
353-1634-7850
Employees
3,200
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$202.50
High Stock Price Forecast
$225.00
Low Stock Price Forecast
$187.00
Forecasted Upside/Downside
+33.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
10.25
P/E Growth
0.94
Net Income
$-329,670,000.00
Net Margins
-0.52%
Pretax Margin
-2.17%
Return on Equity
30.71%
Return on Assets
9.10%

Debt

Debt-to-Equity Ratio
2.07
Current Ratio
3.16
Quick Ratio
2.27

Sales & Book Value

Annual Sales
$3.09 billion
Price / Sales
3.08
Cash Flow
$22.10 per share
Price / Cash Flow
6.85
Book Value
$64.51 per share
Price / Book
2.35

Miscellaneous

Outstanding Shares
62,966,000
Free Float
60,195,000
Market Cap
$9.53 billion
Optionable
Optionable
Beta
0.76

Social Links


Key Executives

  • Bruce C. CozaddBruce C. Cozadd
    Chairman & Chief Executive Officer
  • Daniel N. Swisher
    President
  • Christopher John ToveyChristopher John Tovey
    Chief Operating Officer & Executive Vice President
  • Renée D. Galá
    Chief Financial Officer & Executive Vice President
  • Robert Iannone
    Chief Medical Officer, EVP-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2023?

10 analysts have issued 12 month target prices for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they expect the company's stock price to reach $202.50 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2022?

Jazz Pharmaceuticals' stock was trading at $127.40 at the start of the year. Since then, JAZZ stock has increased by 23.4% and is now trading at $157.25.
View the best growth stocks for 2022 here.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our JAZZ earnings forecast.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $2.60 by $1.60. The specialty pharmaceutical company earned $838.12 million during the quarter, compared to the consensus estimate of $829.98 million. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive trailing twelve-month return on equity of 30.71%. During the same quarter in the prior year, the company earned $3.86 earnings per share.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY22 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $17.20-17.85 for the period, compared to the consensus EPS estimate of $17.30. The company issued revenue guidance of $3.6-3.7 billion, compared to the consensus revenue estimate of $3.64 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.39%), Vanguard Group Inc. (9.35%), State Street Corp (3.64%), LSV Asset Management (2.82%), Polaris Capital Management LLC (2.35%) and Renaissance Technologies LLC (2.06%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $157.25.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.90 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

The company employs 3,200 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 12/5/2022 by MarketBeat.com Staff